BioPharmSignal logoBioPharmSignal

Biotech News

MannKind Reports Third Quarter 2026 Financial Results and Provides Business Update

MannKind (MNKD)MannKindEarnings

Q3 2026 total revenues of $101.9 million, +24% vs. Q3 2025 Q3 2026 commercial product revenue of $45.0 million, +102% vs. Q3 2025 Furoscix ReadyFlow ™ was approved and shipments commenced mid-September Rapid adoption of Furoscix ReadyFlow, making up approximately 75% of the current weekly Furoscix

Related news

MNKDMannKind2026-10-29 20:01 EST

MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026

MNKDMannKind2026-08-05 20:01 EST

MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update

CVRXCVRx2026-11-05 21:05 EST

CVRx Reports Third Quarter 2026 Financial and Operating Results

MLYSMineralys Therapeutics2026-11-04 21:05 EST

Mineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

NAMSNewAmsterdam Pharma2026-11-04 12:30 EST

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results

RYTMRhythm Pharmaceuticals2026-11-03 12:00 EST

Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update

CVRXCVRx2026-10-22 20:30 EST

CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026

ALGSAligos Therapeutics2026-11-06 13:00 EST

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results

ALTAltimmune2026-11-05 13:00 EST

Altimmune to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026

MISTMilestone Pharmaceuticals Inc.2026-11-03 13:00 EST

Milestone Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 13, 2026

View all latest news

MannKind

Inhaled Drug Delivery MannKind develops and commercializes drug-device combinations using Technosphere particles and dry-powder inhalers for rapid, deep-lung delivery. Commercial Portfolio Afrezza is an inhaled mealtime insulin, Tyvaso DPI is manufactured for United Therapeutics, and FUROSCIX provides subcutaneous furosemide for fluid...

Recent company news

MNKDMannKind2026-11-05 21:01 EST

MannKind Reports Third Quarter 2026 Financial Results and Provides Business Update

MNKDMannKind2026-10-29 20:01 EST

MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026

MNKDMannKind2026-10-14 20:01 EST

MannKind to Participate in the Chardan Healthcare Conference

MNKDMannKind2026-10-10 00:00 EST

MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)

MNKDMannKind2026-09-09 10:30 EST

MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management

Stock data

Close
3.76 USD
Market cap
1.06B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States